BEN FENBY APPOINTED CHIEF DEVELOPMENT OFFICER

Month: November 2019 Dr Ben Fenby joins Thirty Group as Chief Development Officer, effective Jan 6, 2020, from an oncology biotech where he was responsible for the late stage portfolio development and strategy. Prior to this Ben worked at AstraZeneca for ten years in...

Jenny Howell appointed Chief Operating Officer

Jenny Howell joins Thirty Group as Chief Operating Officer. Jenny has more than 20 years’ experience in the biotech and pharmaceutical industry, most recently with AstraZeneca/MedImmune where she held a number of senior leadership positions including Chief of Staff to...

MORNINGSIDE VENTURES INVESTS IN THIRTY HOLDINGS

Thirty Holdings Limited completed a £25 million equity investment led by Morningside Ventures, a major investor in the global Life Science sector. The investment enables the Group to accelerate research and development. We are delighted to welcome Isaac Cheng to the...

A NEW NAME FOR A NEW ERA

Thirty Holdings Limited established following a corporate restructure. The Company trading name will be 30 Technology with the name derived from the molecular weight of nitric oxide (30). Edixomed Limited is now a wholly owned subsidiary of Thirty Holdings, focusing...